Brookline Capital Management Comments on MRKR Q1 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Research analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for shares of Marker Therapeutics in a research report issued on Monday, March 31st. Brookline Capital Management analyst L. Cann anticipates that the company will earn ($0.66) per share for the quarter. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.80) EPS and FY2025 earnings at ($4.36) EPS.

A number of other equities analysts have also commented on MRKR. WBB Securities reaffirmed a “strong-buy” rating and set a $12.50 price target on shares of Marker Therapeutics in a research report on Tuesday. Canaccord Genuity Group assumed coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $8.00 target price on the stock.

Marker Therapeutics Stock Performance

MRKR opened at $1.10 on Thursday. The stock has a fifty day moving average of $1.54 and a 200-day moving average of $2.69. The company has a market capitalization of $11.78 million, a P/E ratio of -0.92 and a beta of 1.54. Marker Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $5.99.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Marker Therapeutics had a negative return on equity of 89.63% and a negative net margin of 179.74%. The firm had revenue of $1.22 million for the quarter, compared to analyst estimates of $5.25 million.

Institutional Investors Weigh In On Marker Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MRKR. Aisling Capital Management LP raised its position in shares of Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after buying an additional 11,084 shares in the last quarter. Invst LLC acquired a new position in Marker Therapeutics during the third quarter valued at approximately $56,000. Millennium Management LLC bought a new stake in Marker Therapeutics during the fourth quarter worth $50,000. Northern Trust Corp boosted its holdings in shares of Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after purchasing an additional 21,703 shares in the last quarter. Finally, NEA Management Company LLC raised its holdings in shares of Marker Therapeutics by 51.7% during the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after buying an additional 554,250 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.